Investigational metabolic and adipose-targeting agent for obesity, adipose-tissue dysfunction, and related metabolic conditions (no FDA-approved indication; no registered human clinical trials as of April 2026)

PeptideMulti-factor Neuropeptide Preparation (purified free amino acids and low molecular weight neuropeptide fractions <10 kDa) · Neurorehabilitation after ischemic stroke and traumatic brain injury (approved in 35+ countries including Austria, Germany, Russia, China; NOT FDA-approved in the United States)

Cerebrolysin

Neurorehabilitation after ischemic stroke and traumatic brain injury (approved in 35+ countries including Austria, Germany, Russia, China; NOT FDA-approved in the United States)

PeptideEndogenous neuropeptide fragment; hypothalamic reproductive regulator (KISS1/KISS1R pathway) · Investigational stimulation of the hypothalamic-pituitary-gonadal (HPG) axis: diagnostic evaluation of hypogonadotropic hypogonadism, research in fertility induction, and adjunct investigation alongside testosterone replacement therapy (not FDA-approved for any indication)

Kisspeptin-10

Investigational stimulation of the hypothalamic-pituitary-gonadal (HPG) axis: diagnostic evaluation of hypogonadotropic hypogonadism, research in fertility induction, and adjunct investigation alongside testosterone replacement therapy (not FDA-approved for any indication)

PeptideAnti-inflammatory tripeptide; C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH); a melanocortin-family-derived peptide that acts through non-melanocortin-receptor pathways · Investigational anti-inflammatory therapy for inflammatory bowel disease and other chronic inflammatory conditions (no FDA-approved indication)

KPV

Investigational anti-inflammatory therapy for inflammatory bowel disease and other chronic inflammatory conditions (no FDA-approved indication)

PeptidePyridine Dinucleotide Coenzyme (not a peptide; included in peptide-prescribing practice per common co-prescription alongside longevity and metabolic peptides) · Cellular energetics and mitochondrial support in age-related decline, metabolic dysfunction, and post-exertional recovery (all investigational; no FDA-approved indication for injectable NAD+)

NAD+

Cellular energetics and mitochondrial support in age-related decline, metabolic dysfunction, and post-exertional recovery (all investigational; no FDA-approved indication for injectable NAD+)

PeptideTriple-hormone-receptor agonist (GLP-1, GIP, and glucagon receptors) · Chronic weight management and type 2 diabetes (investigational; Phase 3 TRIUMPH program ongoing. NOT FDA-approved as of April 2026)

Retatrutide

Chronic weight management and type 2 diabetes (investigational; Phase 3 TRIUMPH program ongoing. NOT FDA-approved as of April 2026)

Protocol300mcg/day · 12-24 weeks

AOD-9604 — Fat loss / Body composition

Fat loss / Body composition

Protocol250mcg/day · 4-8 weeks

BPC-157 — Gut healing

Gut healing

Protocol250mcg/day · 6-12 weeks

BPC-157 — Injury repair / Musculoskeletal

Injury repair / Musculoskeletal

Protocol100mcg each · Ongoing (cycle 3-6 months on, 1 month off)

Ipamorelin/CJC-1295 — Anti-aging / GH optimization

Anti-aging / GH optimization

ProtocolPRN (as needed) · As needed

PT-141 (Bremelanotide) — Sexual dysfunction

Sexual dysfunction

ProtocolUp to 2.4mg/week · Ongoing

Semaglutide — Weight loss / Obesity

Weight loss / Obesity

Protocol2.5mg weekly · 4-6 weeks loading, then maintenance

TB-500 — Tissue repair / Wound healing

Tissue repair / Wound healing

Protocol2mg/day · 26 weeks (FDA-approved course)

Tesamorelin — Lipodystrophy / Visceral fat reduction

Lipodystrophy / Visceral fat reduction

BlogClinical Pharmacology · 18 min read · 2026-06-03

How to Interpret Peptide Research for Clinical Use

Clinical guide to evaluate peptide evidence, regulatory status, safety, dosing, and sourcing for responsible patient use.

BlogClinical Pharmacology · 13 min read · 2026-06-02

AI in Peptide Therapy: Benefits and Challenges

How AI speeds peptide therapy research, dosing, and risk checks—boosting efficiency while requiring clinician verification and regulatory vigilance.

BlogRegenerative Medicine · 17 min read · 2026-06-02

Chondroinductive Peptides: Clinical Applications

Overview of chondroinductive peptides for cartilage regeneration: mechanisms, delivery strategies, clinical trials, and translational hurdles.

BlogClinical Pharmacology · 17 min read · 2026-06-01

Emerging Gut-Brain Peptides for Obesity

Overview of multi-agonist gut-brain peptide therapies for obesity, including trial outcomes, mechanisms, and safety considerations.

BlogClinical Pharmacology · 15 min read · 2026-06-01

Ultimate Guide to Peptide Therapy Conferences

Practical guide to choosing, preparing for, and applying insights from peptide therapy conferences for clinicians and researchers.

BlogClinical Pharmacology · 20 min read · 2026-05-30

How to Build a Peptide Protocol for Metabolic Patients

Clinician-led steps to select, dose, monitor, and combine peptides for obesity, type 2 diabetes, and metabolic syndrome.

BlogClinical Pharmacology · 20 min read · 2026-05-29

Peptide Therapy FAQs: Answers for Licensed Prescribers

Practical FAQ for licensed prescribers on patient selection, dosing, safety, and FDA compounding rules for peptide therapy.

BlogClinical Pharmacology · 29 min read · 2026-05-28

Top Peptide Research Updates for Clinicians: 2026 Roundup

2026 clinical summary of peptide advances across weight loss, regeneration, cognition, aesthetics, and immunomodulation.

BlogClinical Pharmacology · 17 min read · 2026-05-27

CJC-1295 vs Ipamorelin: Which GHRH Protocol Fits Best?

Pairing a short-acting GHRH analogue with a ghrelin agonist yields physiological GH pulses that boost recovery, sleep, and body composition.

BlogClinical Pharmacology · 21 min read · 2026-05-26

Peptide Therapy Prescribing Checklist for New Clinicians

Clear checklist for clinicians covering patient evaluation, labs, legal sourcing, dosing, and monitoring of peptide therapies.

BlogClinical Pharmacology · 18 min read · 2026-05-25

Compounded Peptides: Navigating FDA Compliance in 2026

2026 FDA updates tighten rules for compounded peptides: clinical-need documentation, 503A/503B limits, API sourcing, and PCAC reviews.

BlogFunctional Medicine · 18 min read · 2026-05-24

How to Counsel Patients on Peptide Injection Technique

Practical guidance on safe peptide injections: dosing math, reconstitution, storage, site rotation, and sharps disposal.

BlogClinical Pharmacology · 25 min read · 2026-05-24

Semaglutide vs Tirzepatide: Clinical Comparison for Prescribers

Two weekly incretin therapies differ in weight, glycemic control, and long-term safety—prescribe based on cardio‑renal needs vs maximal weight loss.

BlogFunctional Medicine · 32 min read · 2026-05-23

8 Peptide Therapies Gaining Traction in Functional Medicine

Overview of eight peptides used in functional medicine: mechanisms, uses, dosing, and safety considerations.

BlogClinical Education · 8 min read · 2024-12-15

Understanding Peptide Therapy: A Clinical Overview for Prescribers

A comprehensive introduction to peptide therapeutics, their mechanisms of action, and clinical considerations for integration into practice.

BlogRegulatory · 10 min read · 2024-12-10

Regulatory Landscape: What Prescribers Need to Know About Compounded Peptides

Navigate the complex regulatory environment surrounding compounded peptides, including FDA guidelines, state requirements, and best practices for compliance.

BlogClinical Practice · 7 min read · 2024-12-05

Patient Selection Criteria for Peptide Therapy

Evidence-based guidance on identifying appropriate candidates for peptide therapeutics, including assessment protocols and contraindication screening.

Medical Disclaimer

This search tool is provided as an educational resource for healthcare professionals. Search results are drawn from curated clinical content and should not replace professional medical judgment. Always verify information with primary sources and current clinical guidelines.